Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), MannKind Corporation (NASDAQ:MNKD), Questcor Pharmaceuticals Inc (NASDAQ:QCOR), Dyax Corp. (NASDAQ:DYAX), Illumina (NASDAQ:ILMN)

Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) Director Gary E. Frashier unloaded 55,000 shares of the stock on the open market in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $8.00, for a total transaction of $440,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -3.07% in last session and finished the day at $7.58. Traded volume was 13.15million shares … Continue reading Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), MannKind Corporation (NASDAQ:MNKD), Questcor Pharmaceuticals Inc (NASDAQ:QCOR), Dyax Corp. (NASDAQ:DYAX), Illumina (NASDAQ:ILMN)

Kristen Barton06/1806/18

Healthcare Active Movers; Pfizer Inc. (NYSE:PFE), Novavax (NASDAQ:NVAX), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc (NYSE:PFE) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 59,856,772 shares, a growth of 14.0% from the April 30th total of 52,494,773 shares, StockRatingsNetwork.com reports. Currently, 0.9% of the shares of the company are sold short. Pfizer Inc. (NYSE:PFE) stock performance was -1.14% in last session and … Continue reading Healthcare Active Movers; Pfizer Inc. (NYSE:PFE), Novavax (NASDAQ:NVAX), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Jason Knox06/0906/09

FB Nasdaq FB Facebook

New Highs: OmniVision Technologies, Inc. (NASDAQ:OVTI), MannKind Corporation (NASDAQ:MNKD), Intel Corporation (NASDAQ:INTC), Sabre Corp (NASDAQ:SABR)

OmniVision Technologies Inc. (NASDAQ:OVTI) is a publicly traded company with a stock that is set to rocket higher. Revenues for the fourth quarter of fiscal 2014 were $331 million compared to $352 million in the third quarter of fiscal 2014 and $336.2 million in the fourth quarter of fiscal 2013. GAAP net income in the fourth quarter of fiscal 2014 was $15.1 million, or 26 … Continue reading New Highs: OmniVision Technologies, Inc. (NASDAQ:OVTI), MannKind Corporation (NASDAQ:MNKD), Intel Corporation (NASDAQ:INTC), Sabre Corp (NASDAQ:SABR)

Colin Pettis06/0206/02

Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Effective May 15, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) granted an exemption to BlackRock, Inc. (NYSE: BLK), together with its subsidiaries, affiliates and associates (collectively, “BlackRock”) under the Company’s Section 382 Rights Agreement, dated as of October 31, 2013, between the Company and Computershare Trust Company, N.A., as rights agent (the “Rights Agreement”) following the determination by a designated committee of the Board of Directors (the … Continue reading Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Jason Knox05/2205/22

Healthcare ACtive Stocks: Rexahn Pharmaceuticals (NYSEMKT:RNN), Eli Lilly (NYSE:LLY), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Gentiva Health Services (NASDAQ:GTIV)

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) said, “We continue to enroll patients in each of our three clinical trials as expected, and as planned for. By the end of 2014, we expect to achieve key milestones in each trial. In Q4 we expect to have data from our Phase I trial of Supinoxin in cancer patients with solid tumors. We are also scheduled to complete enrollment of … Continue reading Healthcare ACtive Stocks: Rexahn Pharmaceuticals (NYSEMKT:RNN), Eli Lilly (NYSE:LLY), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Gentiva Health Services (NASDAQ:GTIV)

Colin Pettis05/1605/16

Biotech Gainers: MannKind Corporation (NASDAQ:MNKD), Celldex Therapeutics (NASDAQ:CLDX), Dendreon Corporation (NASDAQ:DNDN), Intrexon Corp (NYSE:XON)

MannKind Corp. (NASDAQ: MNKD) was raised to Neutral from Underweight by Piper Jaffray. MannKind Corporation (NASDAQ:MNKD) stock performance was 6.53% in last session and finished the day at $7.01. Traded volume was 16.68million shares in the last session and the average volume of the stock remained 10.11million shares. The beta of the stock remained 1.40. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.30%. Celldex Therapeutics, Inc. … Continue reading Biotech Gainers: MannKind Corporation (NASDAQ:MNKD), Celldex Therapeutics (NASDAQ:CLDX), Dendreon Corporation (NASDAQ:DNDN), Intrexon Corp (NYSE:XON)

Mark DeFrance05/1505/15